Claims
- 1. A set of two isolated cell populations for generating human osteoblast lineage cells, consisting of:
a first cell population comprising pluripotent stem (pPS) cells isolated from a human blastocyst, and a second cell population that proliferates in culture, comprising at least ˜30% pPS derived osteoblasts or osteoblast precursors, identifiable by the criteria that they are progeny of said pPS cells, and have at least one of the following characteristics:
they express osteonectin they express osteocalcin they form an extracellular matrix comprising calcium when cultured in vitro.
- 2. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors express both osteocalcin and type 1 collagen.
- 3. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors have increased alkaline phosphatase activity when cultured with bone morphogenic protein.
- 4. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors form an extracellular matrix comprising calcium when cultured in vitro.
- 5. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors have at least five of the following features: they have morphological characteristics of osteoblast lineage cells, and they express osteocalcin, osteonectin, type 1 collagen, BMP receptors, PTH receptors, and CD105 (endoglin).
- 6. The set of cell populations of claim 1, wherein the osteoblasts or osteoblast precursors cause remineralization of bone.
- 7. The set of cell populations of claim 1, wherein the second cell population has been obtained by differentiating the pPS cells or progeny thereof in a medium containing a bone morphogenic protein (BMP), a ligand for a human TGF-β receptor, or a ligand for a human vitamin D receptor.
- 8. The set of cell populations of claim 1, wherein the second cell population has been obtained by differentiating the pPS cells or progeny thereof in a medium containing dexamethasone, ascorbic acid, and β-glycerophosphate.
- 9. The set of cell populations of claim 1, wherein the second cell population has been obtained by differentiating the pPS cells or progeny thereof in a medium containing BMP-4.
- 10. The set of cell populations of claim 1, wherein the second cell population has been genetically altered to express telomerase reverse transcriptase.
- 11. The set of cell populations of claim 1, wherein the second cell population has been genetically altered to express a bone morphogenic protein.
- 12. The set of cell populations of claim 1, wherein the pPS cells are a line of human embryonic stem cells.
REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. provisional application No. 60/303,732, filed Jul. 6, 2001, pending. The priority application is hereby incorporated herein by reference in its entirety, as is International Patent Publication WO 01/51616.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60303732 |
Jul 2001 |
US |